Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.

Bergamino M, Rullan AJ, Saigí M, Peiró I, Montanya E, Palmero R, Ruffinelli JC, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Cardenal F, Nadal E.

BMC Cancer. 2019 Feb 21;19(1):165. doi: 10.1186/s12885-019-5370-5.

2.

Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.

Antonio M, Saldaña J, Linares J, Ruffinelli JC, Palmero R, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Navarro V, González-Barboteo J, Borràs JM, Cardenal F, Nadal E.

Br J Cancer. 2018 Mar 6;118(5):639-647. doi: 10.1038/bjc.2017.455. Epub 2018 Jan 30.

3.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team.

Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20.

4.

Brain functional connectivity in lung cancer population: an exploratory study.

Simó M, Rifà-Ros X, Vaquero L, Ripollés P, Cayuela N, Jové J, Navarro A, Cardenal F, Bruna J, Rodríguez-Fornells A.

Brain Imaging Behav. 2018 Apr;12(2):369-382. doi: 10.1007/s11682-017-9697-8.

PMID:
28290076
5.

Treatment of resectable stage IIIA non-small cell lung cancer.

Cardenal F, Palmero R.

J Thorac Dis. 2017 Jan;9(1):13-15. doi: 10.21037/jtd.2017.01.08. No abstract available.

6.

Longitudinal Brain Changes Associated with Prophylactic Cranial Irradiation in Lung Cancer.

Simó M, Vaquero L, Ripollés P, Gurtubay-Antolin A, Jové J, Navarro A, Cardenal F, Bruna J, Rodríguez-Fornells A.

J Thorac Oncol. 2016 Apr;11(4):475-86. doi: 10.1016/j.jtho.2015.12.110. Epub 2016 Jan 22.

8.

Opioids for the Management of Dyspnea in Cancer Patients: Evidence of the Last 15 Years--A Systematic Review.

Vargas-Bermúdez A, Cardenal F, Porta-Sales J.

J Pain Palliat Care Pharmacother. 2015;29(4):341-52. doi: 10.3109/15360288.2015.1082005. Epub 2015 Nov 2. Review.

PMID:
26523974
9.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group.

JAMA Oncol. 2015 May;1(2):149-57. doi: 10.1001/jamaoncol.2014.257.

PMID:
26181014
10.

Brain damage following prophylactic cranial irradiation in lung cancer survivors.

Simó M, Vaquero L, Ripollés P, Jové J, Fuentes R, Cardenal F, Rodríguez-Fornells A, Bruna J.

Brain Imaging Behav. 2016 Mar;10(1):283-95. doi: 10.1007/s11682-015-9393-5.

PMID:
26015269
11.

Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

Ajona D, Razquin C, Pastor MD, Pajares MJ, Garcia J, Cardenal F, Fleischhacker M, Lozano MD, Zulueta JJ, Schmidt B, Nadal E, Paz-Ares L, Montuenga LM, Pio R.

PLoS One. 2015 Mar 23;10(3):e0119878. doi: 10.1371/journal.pone.0119878. eCollection 2015.

12.

Cognitive and brain structural changes in a lung cancer population.

Simó M, Root JC, Vaquero L, Ripollés P, Jové J, Ahles T, Navarro A, Cardenal F, Bruna J, Rodríguez-Fornells A.

J Thorac Oncol. 2015 Jan;10(1):38-45. doi: 10.1097/JTO.0000000000000345.

13.

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.

Nadal E, Chen G, Prensner JR, Shiratsuchi H, Sam C, Zhao L, Kalemkerian GP, Brenner D, Lin J, Reddy RM, Chang AC, Capellà G, Cardenal F, Beer DG, Ramnath N.

J Thorac Oncol. 2014 Oct;9(10):1513-22. doi: 10.1097/JTO.0000000000000305.

14.

Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature.

Cardenal F, Nadal E, Jové M, Faivre-Finn C.

Ann Oncol. 2015 Feb;26(2):278-88. doi: 10.1093/annonc/mdu229. Epub 2014 Jun 18. Review.

PMID:
24942274
15.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.

Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2.

PMID:
24636848
16.

Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma.

Nadal E, Chen G, Gallegos M, Lin L, Ferrer-Torres D, Truini A, Wang Z, Lin J, Reddy RM, Llatjos R, Escobar I, Moya J, Chang AC, Cardenal F, Capellà G, Beer DG.

Clin Cancer Res. 2013 Dec 15;19(24):6842-52. doi: 10.1158/1078-0432.CCR-13-0736. Epub 2013 Oct 15.

17.

Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.

Garrido P, Rosell R, Arellano A, Andreu F, Dómine M, Perez-Casas A, Cardenal F, Arnaiz Mdel M, Morán T, Morera R, Isla D, Valencia J, Cobo M, Delgado R, García-Gómez R, Calvo F, Zamora J, Ramos A, Massutí B.

Lung Cancer. 2013 Jul;81(1):84-90. doi: 10.1016/j.lungcan.2013.03.009. Epub 2013 Apr 21.

PMID:
23611405
18.

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.

Provencio M, Camps C, Cobo M, De las Peñas R, Massuti B, Blanco R, Alberola V, Jimenez U, Delgado JR, Cardenal F, Tarón M, Ramírez JL, Sanchez A, Rosell R.

Cancer Chemother Pharmacol. 2012 Dec;70(6):883-90. doi: 10.1007/s00280-012-1985-9. Epub 2012 Sep 29.

PMID:
23053267
19.

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.

Manegold C, Vansteenkiste J, Cardenal F, Schuette W, Woll PJ, Ulsperger E, Kerber A, Eckmayr J, von Pawel J.

Invest New Drugs. 2013 Feb;31(1):175-82. doi: 10.1007/s10637-012-9842-6. Epub 2012 Jul 3.

20.

Paraneoplastic opsoclonus-myoclonus syndrome as a new and single manifestation of relapsing disease in a patient with small cell lung cancer.

Nadal E, Bruna J, Ochoa de Olza M, Antonio M, Cardenal F.

J Thorac Oncol. 2011 May;6(5):968-9. doi: 10.1097/JTO.0b013e318215a257. No abstract available.

Supplemental Content

Loading ...
Support Center